Vidalia

Researchers are compiling information on patients receiving FDA-approved anti-amyloid monoclonal antibodies (mAbs) for Alzheimer's disease through clinics in Georgia. These treatments, including lecanemab and donanemab, have shown promise but require further study to understand their effectiveness and safety in everyday medical practice. The registry is managed by Georgia Memory Net, a statewide initiative supporting early diagnosis and treatment of Alzheimer's and related dementias, providing a strong platform for real-world data collection. Patients receive anti-amyloid mAbs infusions such as lecanemab every two weeks following FDA guidelines. After 18 months, an amyloid PET scan checks for amyloid clearance; if amyloid remains, treatment continues for an additional six months with repeat scans until clearance is confirmed. If a patient progresses to moderate or severe Alzheimer's and amyloid is not cleared, treatment stops. The dosing frequency after amyloid clearance or 18 months is still being determined. Participants are monitored with cognitive and functional assessments, including the Quick Dementia Rating System, Montreal Cognitive Assessment, Functional Activities Questionnaire, and activities of daily living scales, at baseline and every six months for up to five years. The study also involves MRI scans, blood tests, and other clinical evaluations. Care partners provide additional information at follow-ups. The registry compares treated patients with historical data to evaluate benefits, harms, and appropriate use of these therapies over time.